ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2373

UK Clinical Practice Use Of Biologics In Monotherapy For The Treatment Of Patients With Rheumatoid Arthritis

Andrew J. Ostor1, G. Chelliah2, Theodoros Dimitroulas3, Margaret-Mary Gordon4, Nicola Hewson5, JA Mitchell5, Senam Beckley-Kartey6, Hok Pang6 and Jose Saraiva-Ribeiro6, 1Department of Rheumatology, Addenbrookes Hospital, Cambridge, United Kingdom, 2Clinical Trials Unit, Wrightington Hospital, Wigan, United Kingdom, 3Department of Rheumatology, Research and Development, Dudley Group NHS Foundation Trust, Russell’s Hall Hospital, Dudley, United Kingdom, 4Rheumatology Department, Gartnavel General Hospital, Glasgow, United Kingdom, 5Syne Qua Non Ltd., Diss, United Kingdom, 6Medical Department, Roche, Welwyn Garden City, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, clinical practice guidelines and remission

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: NICE guidelines recommend that patients with severe active rheumatoid arthritis (RA) be treated with a biologic disease‑modifying anti‑rheumatic drug as monotherapy (bDMARD mono) if they respond inadequately to 2 traditional DMARDs and are intolerant to methotrexate (MTX). Registry and healthcare utilisation data have shown that around one-third of RA patients receive their biologic treatment as monotherapy. We intended to better understand the current management of RA patients with biologics in monotherapy, particularly why patients receive monotherapy and how effective this is in daily practice.

Methods: This UK wide chart review was conducted in 26 Rheumatology Hospitals between September 2012 and May 2013 and data from 309 RA patients, who had been prescribed a bDMARD mono, were collected retrospectively. We present data from an interim analysis of 150 patients.

Results: Mean age was 62.4 yrs. and mean duration of disease was 16.3 yrs. The majority of patients were female (109). 102 (74.4%) patients were Rheumatoid factor positive (n=137) and 34 (36.6%) anti-CCP positive (n=93). With regards to past RA treatment (prior to switch to monotherapy, n=61), the most frequently used bDMARDs mono (at any time prior to switch) were etanercept (ETN; 19.3%),adalimumab (ADA; 14%), certolizumab pegol (CZP, 7.3%), rituximab (RTX, 4.7%) and tocilizumab (TCZ, 2.7%). 55 (36.7%) patients had used two or more bDMARD mono. The most frequently used traditional DMARDs (n=146) were methotrexate (MTX; 92%), sulfasalazine (74.7%) and hydroxychloroquine (42.7%).With regards to current RA treatment (all patients receiving bDMARD mono), the most frequently used bDMARDs were ETN (42.7%), ADA (26%), TCZ (10.7%), RTX (9.3%) and CZP (8%). The main reason for prescribing bDMARD mono (n=150) was unknown (88%, assumed clinician decision). Others were patient preference (6.7%) and contra-indication (7.3%). Nearly a quarter of patients were on non-NICE approved monotherapy drug and only 10.7% were in DAS28 ESR remission.

Conclusion:

Registry and healthcare utilisation data have shown that around one-third of RA patients receive their biologic treatment as monotherapy. The results of this audit draws attention to a patient population where treatment outcomes with bDMARD monotherapy are still not optimal (only 10.7% were in DAS28 ESR remission). 76.7% of the patients were treated with the above NICE approved TNF inhibitor. 55 (36.7%) patients had used two or more bDMARD monotherapies indicating that there are a significant number of patients where combination therapy with traditional DMARDs is not an option. As remission is the treatment goal and only 10.7% of patients were in remission there is an unmet medical need and therefore alternative treatment options should be explored to ensure better treatment outcomes for patients with this debilitating disease.


Disclosure:

A. J. Ostor,
None;

G. Chelliah,

Roche Pharmaceuticals,

2;

T. Dimitroulas,

Roche Pharmaceuticals,

2;

M. M. Gordon,

Roche Pharmaceuticals,

2;

N. Hewson,

Roche Pharmaceuticals,

5;

J. Mitchell,

Roche Pharmaceuticals,

5;

S. Beckley-Kartey,

Roche Pharmaceuticals,

3;

H. Pang,

Roche Pharmaceuticals,

3;

J. Saraiva-Ribeiro,

Roche Pharmaceuticals,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uk-clinical-practice-use-of-biologics-in-monotherapy-for-the-treatment-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology